BAFF levels in patients with ankylosing spondylitis and response to anti-tumor necrosis factor treatment by Niederer, Fabienne et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
BAFF levels in patients with ankylosing spondylitis and response to
anti-tumor necrosis factor treatment
Niederer, Fabienne; Scherer, Almut; Kyburz, Diego; Gay, Renate E; Gay, Steffen; Michel, Beat A;
Ciurea, Adrian
Abstract: Unspecified
DOI: 10.1016/j.jbspin.2012.10.004
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-68136
Originally published at:
Niederer, Fabienne; Scherer, Almut; Kyburz, Diego; Gay, Renate E; Gay, Steffen; Michel, Beat A; Ciurea,
Adrian (2013). BAFF levels in patients with ankylosing spondylitis and response to anti-tumor necrosis
factor treatment. Joint Bone Spine, 80(4):433-434. DOI: 10.1016/j.jbspin.2012.10.004
BAFF levels in patients with ankylosing spondylitis and response to 
anti-tumor necrosis factor treatment 
 
Fabienne Niederer1, Almut Scherer2, Diego Kyburz3, Renate E. Gay1, Steffen Gay1,  
Beat A. Michel3, Adrian Ciurea3 
 
1Center of Experimental Rheumatology, University Hospital, Zurich, Switzerland 
2University of Zurich, Zurich, Switzerland 
3Department of Rheumatology, University Hospital, Zurich, Switzerland 
 
Keywords: Ankylosing  spondylitis, BAFF, BLyS, anti-tumor necrosis factor treatment 
 
Corresponding author 
Adrian Ciurea, M.D. 
Department of Rheumatology 
University Hospital Zurich 
Gloriastrasse 25 
CH-8091 Zurich, Switzerland 
Tel.: +41 44 255 29 58 
Fax.: +41 44 255 44 15 
Email: adrian.ciurea@usz.ch  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The serum levels of B cell-activating factor of the TNF family (BAFF), also called B 
lymphocyte stimulator (BLyS), have been shown to be increased in patients with several 
inflammatory rheumatic diseases [1-3]. Although B cells are not commonly associated with the 
pathogenesis of ankylosing spondylitis (AS), some findings corroborate their potential 
involvement. Dense infiltrations of B cells were found in the spine of patients with active 
inflammation [4]. Moreover, anti-tumour necrosis factor treatment (aTNF)-naïve patients 
showed a good treatment response to B cell depletion with rituximab [5]. As BAFF is a potent 
B cell survival and maturation factor, we analyzed BAFF levels in AS patients before and after 
aTNF. The study protocol has been approved by the Institutional Review Board of the Canton 
of Zurich. 
Serum samples were obtained from 49 patients with definite AS, as well as from 35 healthy 
controls (HC), after written informed consent. aTNF with adalimumab (n=15) or infliximab 
(n=20) was initiated in 35 patients with Bath AS Disease Activity Index (BASDAI) levels > 4, 
according to the decision of the treating rheumatologist. Serum was obtained again 3 months 
later in these subjects. Treatment response was defined as a 50% relative decrease in 
BASDAI or an absolute decrease in 2 BASDAI points on a scale 0-10. BAFF serum levels 
were measured using a commercially available ELISA (R&D systems, Minneapolis, 
Minnesota, USA).  
Baseline (BL) serum BAFF levels were lower in AS patients compared to HC (median 1.1 
ng/ml [5th-95th percentile: 1-1.9] vs. 1.5 ng/ml [5th-95th percentile: 0.8-2.0] respectively; 
p=0.002). Only in 3/49 AS patients BAFF levels exceeded slightly the upper cutoff limit of 2.1 
ng/ml (corresponding to the mean +2SD of the levels in HC). BL BAFF levels did not correlate 
with BASDAI, CRP, HLA-B27 positivity, disease duration or co-medication with DMARDs. The 
median BAFF levels increased modestly 3 months after initiation of aTNF (BAFF3mo), from 
1.06 ng/ml to 1.38 ng/ml (Wilcoxon paired sign rank test 95% confidence interval (CI) of 
increase: +0.09;+0.39; p=0.003) and nearly reached levels observed in HC. The increase was 
observed in patients responding to aTNF as well as in non-responders (0.26 ng/ml [95% CI 
0.09-0.46] vs. 0.18 ng/ml [95% CI -0.1-0.52]). After stepwise variable selection of a multiple 
regression model for BAFF3mo as a function of BL BAFF and the other variables mentioned 
above, we found that BAFF3mo was 1.32-fold higher in HLA-B27 positive patients and was 
positively related to BL CRP (overall p-value of model <0.002, adjusted R2=0.43). 
As a conclusion, BAFF is not elevated in AS patients, in contrast to other chronic inflammatory 
rheumatic diseases [2,3]. Therapeutic inhibition of the BAFF pathway with belimumab [6] or 
atacicept [7] is therefore not warranted in AS. As opposed to patients with rheumatoid arthritis 
showing a decrease in BAFF levels following a good response to TNF inhibition [8], we 
observed a slight increase in BAFF after aTNF. Whether this finding might explain the fact that 
B cell depletion with rituximab is not very effective following aTNF in AS remains unclear.  
Figures 
 
                                        
Fig. 1. Serum levels of BAFF (ng/ml) in individual patients with ankylosing spondylitis (AS) 
compared to healthy controls (HC). The broken line indicates the cut-off (defined as mean 
+2SD of levels in HC). 
 
Fig. 2. Effect of TNF inhibitor treatment on BAFF serum levels in treatment responders vs. 
non-responders. Serum samples were collected at baseline (BL) and 3 months treatment 
initiation. 
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